Aptorum Group Limited - Class A Ordinary Shares (APM): Price and Financial Metrics
GET POWR RATINGS... FREE!
APM POWR Grades
- Sentiment is the dimension where APM ranks best; there it ranks ahead of 86.17% of US stocks.
- APM's strongest trending metric is Growth; it's been moving down over the last 31 weeks.
- APM ranks lowest in Stability; there it ranks in the 10th percentile.
APM Stock Summary
- APM's price/sales ratio is 108.62; that's higher than the P/S ratio of 96.62% of US stocks.
- With a year-over-year growth in debt of -83.06%, Aptorum Group Ltd's debt growth rate surpasses only 2.89% of about US stocks.
- Revenue growth over the past 12 months for Aptorum Group Ltd comes in at 137.71%, a number that bests 95.48% of the US stocks we're tracking.
- Stocks that are quantitatively similar to APM, based on their financial statements, market capitalization, and price volatility, are AGX, ITI, THRM, PCYO, and CSGS.
- APM's SEC filings can be seen here. And to visit Aptorum Group Ltd's official web site, go to www.aptorumgroup.com.
APM Stock Price Chart Interactive Chart >
APM Price/Volume Stats
|Current price||$2.90||52-week high||$14.23|
|Prev. close||$2.84||52-week low||$1.16|
|Day high||$2.91||Avg. volume||879,086|
|50-day MA||$2.72||Dividend yield||N/A|
|200-day MA||$2.69||Market Cap||98.66M|
Aptorum Group Limited - Class A Ordinary Shares (APM) Company Bio
Aptorum Group Ltd. is a pharmaceutical company, which engages in the development and commercialization of therapeutic and diagnostic technologies. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, and other disease areas. The Non-Therapeutics segment encompasses the development of surgical robotics and medical devices; and the activities of AML Clinic. The company was founded by Ian Huen on September 13, 2010 and is headquartered in Hong Kong.
APM Latest News Stream
|Loading, please wait...|
APM Latest Social Stream
View Full APM Social Stream
Latest APM News From Around the Web
Below are the latest news stories about Aptorum Group Ltd that investors may wish to consider to help them evaluate APM as an investment opportunity.
Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) ("Aptorum Group", the "Company"), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced that Mr. Ian Huen, Founder, Chief Executive Officer and Executive Director of the Company, through his wholly owned investment company Jurchen Investments Limited, has purchased an aggregate of 1,387,925 Class A Ordinary Shares in the Company at $2.882 per share, representing a 10% premium to the last closing price.
Verastem's VS-6766/Defactinib Combo Gets Breakthrough Therapy Tag For Ovarian Cancer; BTIG Upgrades Stock
View more earnings on VSTMSee more from BenzingaClick here for options trades from BenzingaAptorum's Shares Jump After ALS-4 Targeting Staphylococcus Aureus Shows Encouraging Action In Early-Stage Study4D Pharma's Stock Shoots Higher on Positive Data from Irritable Bowel Syndrome Candidate© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Aptorum's Shares Jump After ALS-4 Targeting Staphylococcus Aureus Shows Encouraging Action In Early-Stage Study
Aptorum Group Limited (NASDAQ: APM) has completed two initial cohorts of the single-dose ascending dose (SAD) portion of the Phase 1 trial evaluating ALS-4 small molecule targeting Staphylococcus aureus. Total 6 cohorts for SAD and three cohorts for multiple ascending doses (MAD) have been planned. Dosing and safety reviews of Cohort A (25mg) and Cohort B (50mg) have been completed. No human subjects were dropped out of the studies, and there were no Serious Adverse Events observed. In addition, no relevant clinical changes regarding vital signs, ECG, clinical laboratory test results, and physical examinations were observed compared to the relevant baseline. Cohort C (100mg) studies have been initiated. The company also completed the Pre-IND meeting with the FDA related to SACT-1, a rep...
Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus aureus and Positive Pre-IND Progress for SACT-1 Targeting Neuroblastoma
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases.
Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) ("Aptorum Group"), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced that Mr. Darren Lui, President and Executive Director of Aptorum Group, will present at the Benzinga Global Small Cap Conference.
APM Price Returns